Latest From Theradiag
Device firms closed the final quarter of 2012 with $1.1 billion in financing, led by Volcano’s debt offering. Takeovers of Gambro and PSS Medical topped the device M&A list. At $196 million, Q4 diagnostic financing was the lowest quarter of the year, but IPOs returned with three public debuts. Amgen’s $415 million acquisition of deCODE was the largest diagnostic M&A.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Therapeutic Drug Monitoring
- Therapeutic Areas
- Biomedical Diagnostics
- Western Europe
- Parent & Subsidiaries
- Senior Management
Michel Finance, CEO
Ermis Parussini, Exec. Dir., Oper. & R&D
Odile Prigneau, PhD, Dir., Mktg. & Bus. Dev.
- Contact Info
Phone: (33) 64 62 10 12
Actipole No. 25 Boulevard de Beaubourg
Marne la Vallée, 77435
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.